This $1.8 million firm fixed price contract was awarded by the National Institutes of Health National Institute of Allergy and Infectious Diseases to Inimmune Corp. of Missoula, Montana. The contract is for Phase II of the Small Business Innovation Research program topic 091 to develop a new Toll-like receptor 4 agonist for the treatment of allergic rhinitis. The research and development effort will be performed in Missoula from September 2021 through August 2023. This total small business set-aside award was made under a broader NIH/CDC SBIR solicitation seeking innovative solutions aligned with the public health and biomedical research missions of the funding agencies.
Generated 12/29/23, 3:50 PM